中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

胰腺癌综合诊治指南(2018版)

中国抗癌协会胰腺癌专业委员会

引用本文:
Citation:

胰腺癌综合诊治指南(2018版)

DOI: 10.3969/j.issn.1001-5256.2018.10.011
详细信息
  • 中图分类号: R735.9

Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2018 version)

  • 摘要:

    胰腺癌发病率逐年增加,位列癌症致死原因第5位。尽管胰腺癌诊治现状不容乐观,但在肿瘤学新理念的推动下其临床诊疗水平近年仍取得明显进步。中国抗癌协会胰腺癌专业委员会结合现状制订了最新版《胰腺癌综合诊治指南(2018版)》,以期规范和提高中国胰腺癌诊治水平。其内容主要包括胰腺癌的诊断和分型、分期,以外科、化疗和放疗为主的综合治疗,以及患者全程管理。本指南具有鲜明的特点,除规范了诊治策略外,还以问题导向式的章节结构对胰腺癌综合诊治中的19个热点问题予以讨论和推荐,包括:对活组织检查和标本部位进行的选择,胰腺癌临床诊断标准的制定,肿瘤可切除性的评估,术前减黄的必要性及方式,微创手术在胰腺癌中的应用,扩大切除对手术疗效的影响,标准胰头癌根治术中是否联合第16组淋巴结清扫,血清肿瘤标志物对治疗疗效的预测,以及新辅助治疗在可切除患者中的应用等。本指南的颁布将有利于专科医师对胰腺癌诊治的全面认知,能进一步规范和提高不同层次医师的诊治水平。

     

  • [1] SIEGEL RL, MILLER KD, JEMAL A.Cancer statistics, 2018[J].CA Cancer J Clin, 2018, 68 (1) :7-30.
    [2]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.
    [3]CHEN W, SUN K, ZHENG R, et al.Cancer incidence and mortality in China, 2014[J].Chin J Cancer Res, 2018, 30 (1) :1-12.
    [4]LI D, MORRIS JS, LIU J, et al.Body mass index and risk, age of onset, and survival in patients with pancreatic cancer[J].JAMA, 2009, 301 (24) :2553-2562.
    [5]BAGNARDI V, ROTA M, BOTTERI E, et al.Alcohol consumption and site-specific cancer risk:A comprehensive dose-response meta-analysis[J].Br J Cancer, 2015, 112 (3) :580-593.
    [6]CAMARA SN, YIN T, YANG M, et al.High risk factors of pancreatic carcinoma[J].J Huazhong Univ Sci Technolog Med Sci, 2016, 36 (3) :295-304.
    [7]GHIORZO P, FORNARINI G, SCIALLERO S, et al.CDKN2A is the main susceptibility gene in Italian pancreatic cancer families[J].J Med Genet, 2012, 49 (3) :164-170.
    [8]ZHEN DB, RABE KG, GALLINGER S, et al.BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer:A PAC-GENE study[J].Genet Med, 2015, 17 (7) :569-577.
    [9]PORUK KE, GAY DZ, BROWN K, et al.The clinical utility of CA 19-9 in pancreatic adenocarcinoma:Diagnostic and prognostic updates[J].Curr Mol Med, 2013, 13 (3) :340-351.
    [10]LUO G, LIU C, GUO M, et al.CA19-9-Low&Lewis (+) pancreatic cancer:A unique subtype[J].Cancer Lett, 2017, 385:46-50.
    [11]LIAO WC, TU YK, WU MS, et al.Blood glucose concentration and risk of pancreatic cancer:Systematic review and dose-response meta-analysis[J].BMJ, 2015, 350:g7371.
    [12]XU J, CAO Z, LIU W, et al.Plasma miRNAs effectively distinguish patients with pancreatic cancer from controls:A multicenter study[J].Ann Surg, 2016, 263 (6) :1173-1179.
    [13]XU L, LI Q, XU D, et al.hsa-miR-141 downregulates TM4SF1to inhibit pancreatic cancer cell invasion and migration[J].Int JOncol, 2014, 44 (2) :459-466.
    [14]MELO SA, LUECKE LB, KAHLERT C, et al.Glypican-1 identifies cancer exosomes and detects early pancreatic cancer[J].Nature, 2015, 523 (7559) :177-182.
    [15]COHEN JD, JAVED AA, THOBURN C, et al.Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers[J].Proc Natl Acad Sci U SA, 2017, 114 (38) :10202-10207.
    [16]MA L, TIAN X, GUO H, et al.Long noncoding RNA H19 derived miR-675 regulates cell proliferation by down-regulating E2F-1in human pancreatic ductal adenocarcinoma[J].J Cancer, 2018, 9 (2) :389-399.
    [17]LI W, ZHANG X, LU X, et al.5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers[J].Cell Res, 2017, 27 (10) :1243-1257.
    [18]AL-HAWARY MM, FRANCIS IR, CHARI ST, et al.Pancreatic ductal adenocarcinoma radiology reporting template:Consensus statement of the society of abdominal radiology and the American pancreatic association[J].Gastroenterology, 2014, 146 (1) :291-304.
    [19]TIRKES T, SANDRASEGARAN K, SANYAL R, et al.Secretinenhanced MR cholangiopancreatography:Spectrum of findings[J].Radiographics, 2013, 33 (7) :1889-1906.
    [20]XU HX, CHEN T, WANG WQ, et al.Metabolic tumour burden assessed by18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection[J].Eur J Nucl Med Mol Imaging, 2014, 41 (6) :1093-1102.
    [21]CANTO MI, GOGGINS M, HRUBAN RH, et al.Screening for early pancreatic neoplasia in high-risk individuals:A prospective controlled study[J].Clin Gastroenterol Hepatol, 2006, 4 (6) :766-781.
    [22]OKASHA HH, NAGA MI, ESMAT S, et al.Endoscopic ultrasound-guided fine needle aspiration versus percutaneous ultrasoundguided fine needle aspiration in diagnosis of focal pancreatic masses[J].Endosc Ultrasound, 2013, 2 (4) :190-193.
    [23]LI JH, HE R, LI YM, et al.Endoscopic ultrasonography for tumor node staging and vascular invasion in pancreatic cancer:A meta-analysis[J].Dig Surg, 2014, 31 (4-5) :297-305.
    [24]BAILEY P, CHANG DK, NONES K, et al.Genomic analyses identify molecular subtypes of pancreatic cancer[J].Nature, 2016, 531 (7952) :47-52.
    [25]WADDELL N, PAJIC M, PATCH AM, et al.Whole genomes redefine the mutational landscape of pancreatic cancer[J].Nature, 2015, 518 (7540) :495-501.
    [26]DU Y, ZHAO B, LIU Z, et al.Molecular subtyping of pancreatic cancer:Translating genomics and transcriptomics into the clinic[J].J Cancer, 2017, 8 (4) :513-522.
    [27]FERRONE CR, LEVINE DA, TANG LH, et al.BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma[J].JClin Oncol, 2009, 27 (3) :433-438.
    [28]CONNOR AA, DENROCHE RE, JANG GH, et al.Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma[J].JAMA Oncol, 2017, 3 (6) :774-783.
    [29]CHANTRILL LA, NAGRIAL AM, WATSON C, et al.Precision medicine for advanced pancreas cancer:The individualized molecular pancreatic cancer therapy (IMPa CT) trial[J].Clin Cancer Res, 2015, 21 (9) :2029-2037.
    [30]COLLISSON EA, SADANANDAM A, OLSON P, et al.Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy[J].Nat Med, 2011, 17 (4) :500-503.
    [31]MOFFITT RA, MARAYATI R, FLATE EL, et al.Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma[J].Nat Genet, 2015, 47 (10) :1168-1178.
    [32]National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology (NCCN guidelines) :Pancreatic adenocarcinoma[EB/OL].[2018-04-27].https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
    [33]LIU L, XU HX, HE M, et al.A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma:Implications for AJCC-TNM staging[J].Surgery, 2018, 163 (6) :1280-1294.
    [34]SHI S, HUA J, LIANG C, et al.Proposed modification of the 8th edition of the AJCC staging system for pancreatic ductal adenocarcinoma[J].Ann Surg, 2018.[Epub ahead of print]
    [35]SHEN BY, SHI YS.Present situation and prospect of Da Vinci robot-assisted pancreatic surgery[J].Chin J Dig Surg, 2017, 16 (8) :797-799. (in Chinese) 沈柏用, 施昱晟.达芬奇机器人手术系统辅助胰腺手术的现状与展望[J].中华消化外科杂志, 2017, 16 (8) :797-799.
    [36]ZHANG H, WU X, ZHU F, et al.Systematic review and meta-analysis of minimally invasive versus open approach for pancreaticoduodenectomy[J].Surg Endosc, 2016, 30 (12) :5173-5184.
    [37]CAO F, LI J, LI A, et al.Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer:A systemic review and meta-analysis[J].BMC Surg, 2017, 17 (1) :67.
    [38]TAKAHASHI H, AKITA H, TOMOKUNI A, et al.Preoperative Gemcitabine-based chemoradiation therapy for borderline resectable pancreatic cancer:Impact of venous and arterial involvement status on surgical outcome and pattern of recurrence[J].Ann Surg, 2016, 264 (6) :1091-1097.
    [39]FRIGERIO I, REGI P, GIARDINO A, et al.Downstaging in stage IV pancreatic cancer:A new population eligible for surgery?[J].Ann Surg Oncol, 2017, 24 (8) :2397-2403.
    [40]OETTLE H, NEUHAUS P, HOCHHAUS A, et al.Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer:The CONKO-001 randomized trial[J].JAMA, 2013, 310 (14) :1473-1481.
    [41]KHORANA AA, MANGU PB, BERLIN J, et al.Potentially curable pancreatic cancer:American society of clinical oncology clinical practice guideline update[J].J Clin Oncol, 2017, 35 (20) :2324-2328.
    [42]KHORANA AA, MANGU PB, BERLIN J, et al.Potentially curable pancreatic cancer:American society of clinical oncology clinical practice guideline[J].J Clin Oncol, 2016, 34 (21) :2541-2556.
    [43]LIU L, XU H, WANG W, et al.A preoperative serum signature of CEA+/CA125+/CA19-9≥1000 U/m L indicates poor outcome to pancreatectomy for pancreatic cancer[J].Int J Cancer, 2015, 136 (9) :2216-2227.
    [44]NEOPTOLEMOS JP, MOORE MJ, COX TF, et al.Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma:The ESPAC-3 periampullary cancer randomized trial[J].JAMA, 2012, 308 (2) :147-156.
    [45]NEOPTOLEMOS JP, PALMER DH, GHANEH P, et al.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) :A multicentre, open-label, randomised, phase 3 trial[J].Lancet, 2017, 389 (10073) :1011-1024.
    [46]UESAKA K, BOKU N, FUKUTOMI A, et al.Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer:A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) [J].Lancet, 2016, 388 (10041) :248-257.
    [47]RAHMA OE, DUFFY A, LIEWEHR DJ, et al.Second-line treatment in advanced pancreatic cancer:A comprehensive analysis of published clinical trials[J].Ann Oncol, 2013, 24 (8) :1972-1979.
    [48]SAHIN IH, ASKAN G, HU ZI, et al.Immunotherapy in pancreatic ductal adenocarcinoma:An emerging entity?[J].Ann Oncol, 2017, 28 (12) :2950-2961.
    [49]FENG M, XIONG G, CAO Z, et al.PD-1/PD-L1 and immunotherapy for pancreatic cancer[J].Cancer Lett, 2017, 407:57-65.
    [50]VON HOFF DD, ERVIN T, ARENA FP, et al.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J].NEngl J Med, 2013, 369 (18) :1691-1703.
    [51]WANG-GILLAM A, LI CP, BODOKY G, et al.Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1) :A global, randomised, open-label, phase 3 trial[J].Lancet, 2016, 387 (10018) :545-557.
    [52]CONROY T, DESSEIGNE F, YCHOU M, et al.FOLFIRINOXversus gemcitabine for metastatic pancreatic cancer[J].N Engl JMed, 2011, 364 (19) :1817-1825.
    [53]SUDO K, ISHIHARA T, HIRATA N, et al.Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer[J].Cancer Chemother Pharmacol, 2014, 73 (2) :389-396.
    [54]GILL S, KO YJ, CRIPPS C, et al.PANCREOX:A randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy[J].J Clin Oncol, 2016, 34 (32) :3914-3920.
    [55]UENO H, IOKA T, IKEDA M, et al.Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan:GEST study[J].J Clin Oncol, 2013, 31 (13) :1640-1648.
    [56]CUNNINGHAM D, CHAU I, STOCKEN DD, et al.Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer[J].J Clin Oncol, 2009, 27 (33) :5513-5518.
    [57]OETTLE H, RIESS H, STIELER JM, et al.Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer:Outcomes from the CONKO-003 trial[J].J Clin Oncol, 2014, 32 (23) :2423-2429.
    [58]ZHU CP, SHI J, CHEN YX, et al.Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer:A meta-analysis[J].Radiother Oncol, 2011, 99 (2) :108-113.
    [59]HUGUET F, GIRARD N, GUERCHE CS, et al.Chemoradiotherapy in the management of locally advanced pancreatic carcinoma:Aqualitative systematic review[J].J Clin Oncol, 2009, 27 (13) :2269-2277.
    [60]JIN Z, DU Y, LI Z, et al.Endoscopic ultrasonography-guided interstitial implantation of iodine 125-seeds combined with chemotherapy in the treatment of unresectable pancreatic carcinoma:A prospective pilot study[J].Endoscopy, 2008, 40 (4) :314-320.
    [61]DU Y, JIN Z, MENG H, et al.Long-term effect of gemcitabinecombined endoscopic ultrasonography-guided brachytherapy in pancreatic cancer[J].J Interv Gastroenterol, 2013, 3 (1) :18-24.
    [62]JONES WE 3rd, SUH WW, ABDEL-WAHAB M, et al.ACR appropriateness criteriaresectable pancreatic cancer[J].Am J Clin Oncol, 2017, 40 (2) :109-117.
    [63]KATZ MH, CRANE CH, VARADHACHARY G.Management of borderline resectable pancreatic cancer[J].Semin Radiat Oncol, 2014, 24 (2) :105-112.
    [64]LIU Z, LUO G, GUO M, et al.Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer[J].Pancreatology, 2015, 15 (3) :253-258.
    [65]HERMAN JM, SWARTZ MJ, HSU CC, et al.Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas:Results of a large, prospectively collected database at the Johns Hopkins Hospital[J].J Clin Oncol, 2008, 26 (21) :3503-3510.
    [66]BALABAN EP, MANGU PB, KHORANA AA, et al.Locally advanced, unresectable pancreatic cancer:American society of clinical oncology clinical practice guideline[J].J Clin Oncol, 2016, 34 (22) :2654-2668.
    [67]HURT CN, FALK S, CROSBY T, et al.Long-term results and recurrence patterns from SCALOP:A phase II randomised trial of gemcitabine-or capecitabine-based chemoradiation for locally advanced pancreatic cancer[J].Br J Cancer, 2017, 116 (10) :1264-1270.
    [68]KARAKAS Y, LACIN S, YALCIN S.Recent advances in the management of pancreatic adenocarcinoma[J].Expert Rev Anticancer Ther, 2018, 18 (1) :51-62.
    [69]LUCENTEFORTE E, LA VECCHIA C, SILVERMAN D, et al.Alcohol consumption and pancreatic cancer:A pooled analysis in the international pancreatic cancer case-control consortium (PanC4) [J].Ann Oncol, 2012, 23 (2) :374-382.
    [70]HONG GB, ZHOU JX, SUN HB, et al.Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma[J].Asian Pac J Cancer Prev, 2012, 13 (6) :2669-2673.
    [71]CHEN Y, WANG XL, WANG JH, et al.Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer[J].Anticancer Drugs, 2014, 25 (8) :958-963.
    [72]FEARON K, STRASSER F, ANKER SD, et al.Definition and classification of cancer cachexia:An international consensus[J].Lancet Oncol, 2011, 12 (5) :489-495.
    [73]BEATTY GL, CHIOREAN EG, FISHMAN MP, et al.CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans[J].Science, 2011, 331 (6024) :1612-1616.
    [74]RHIM AD, OBERSTEIN PE, THOMAS DH, et al.Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma[J].Cancer Cell, 2014, 25 (6) :735-747.
    [75]ROBERTS KJ, KERSHNER AM, BEACHY PA.The stromal niche for epithelial stem cells:A template for regeneration and a brake on malignancy[J].Cancer Cell, 2017, 32 (4) :404-410.
    [76]MOORE MJ, GOLDSTEIN D, HAMM J, et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:A phase III trial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol, 2007, 25 (15) :1960-1966.
    [77]SCHULTHEIS B, REUTER D, EBERT MP, et al.Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer:A multicenter, randomized phase IIb study[J].Ann Oncol, 2017, 28 (10) :2429-2435.
    [78]MARTIN RC 2nd, KWON D, CHALIKONDA S, et al.Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation:Safety and efficacy[J].Ann Surg, 2015, 262 (3) :486-494.
    [79] ZHAO YP.Attach importance to the multidisciplinary diagnosis and treatment of pancreatic cancer[J].Chin J Surg, 2016, 54 (11) :801-803. (in Chinese) 赵玉沛.重视胰腺癌的多学科诊疗[J].中华外科杂志, 2016, 54 (11) :801-803.
    [80]RIEMANN JF, EICKHOFF A.Pancreas:Preoperative biliary drainage for pancreatic cancer[J].Nat Rev Gastroenterol Hepatol, 2010, 7 (6) :308-309.
    [81]van der GAAG NA, RAUWS EA, van EIJCK CH, et al.Preoperative biliary drainage for cancer of the head of the pancreas[J].NEngl J Med, 2010, 362 (2) :129-137.
    [82]HARTWIG W, STROBEL O, HINZ U, et al.CA19-9 in potentially resectable pancreatic cancer:Perspective to adjust surgical and perioperative therapy[J].Ann Surg Oncol, 2013, 20 (7) :2188-2196.
    [83]O'BRIEN DP, SANDANAYAKE NS, JENKINSON C, et al.Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer:Implications for early disease detection[J].Clin Cancer Res, 2015, 21 (3) :622-631.
    [84]KONDO S.Japanese pancreas society staging systems for pancreatic cancer//NEOPTOLEMOS JP, URRUTIA R, ABBRUZZESE J, et al.Pancreatic Cancer[M].New York:Springer, 2010:1035-1050.
    [85]LIU C, CHEN R, CHEN Y, et al.Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer?A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC) [J].Int J Oncol, 2015, 47 (4) :1512-1516.
    [86]CAPELLO M, LEE M, WANG H, et al.Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOXtherapy in pancreatic ductal adenocarcinoma[J].J Natl Cancer Inst, 2015, 107 (8) :djv132.
  • 加载中
计量
  • 文章访问数:  6298
  • HTML全文浏览量:  441
  • PDF下载量:  3859
  • 被引次数: 0
出版历程
  • 出版日期:  2018-10-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回